Business Wire·Nov 9, 2026, 4:35 AM ET

Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Qureight's Fibr8 quantitative imaging biomarker is designated as a secondary endpoint in Contineum's Phase 2 PROPEL-IPF clinical trial.
The PROPEL-IPF trial evaluates the safety, efficacy, & tolerability of Contineum's lead candidate PIPE-791 in approximately 324 idiopathic pulmonary fibrosis (IPF) patients.
PIPE-791 targets the lysophosphatidic acid receptor 1 (LPAR1), a clinically validated target for IPF.
The trial employs a global, randomized, double-blind, placebo-controlled design with a 26-week treatment period for once-daily oral administration.
Forced Vital Capacity (FVC) serves as the primary endpoint to measure lung function, while Fibr8 provides structural assessment by quantifying fibrosis burden on High-Resolution Computed Tomography (HRCT).
Combining physiological & imaging measurements aims to generate evidence supporting the use of quantitative CT as a sensitive measure of therapeutic response in antifibrotic drug development.
This partnership follows a recent European Respiratory Journal viewpoint by Qureight advocating for fibrosis quantification as a key structural imaging biomarker in antifibrotic trials.
Qureight aims to use data from PROPEL-IPF to pursue formal regulatory qualification of imaging biomarkers as endpoints in future antifibrotic studies.